Product Description
99% up by HPLC GMP DMF Candesartan cilexetil 145040-37-5
AI Product Description
*The following content is generated by AI and is for reference only.
Candesartan cilexetil, identified by the CAS Registry Number 145040-37-5, is a widely utilized pharmaceutical intermediate and active pharmaceutical ingredient (API) precursor in the global healthcare sector. Chemically, it serves as an ester prodrug of candesartan, a potent angiotensin II receptor blocker (ARB). Its molecular formula is C28H30N6O6, with a molecular weight of approximately 538.57 g/mol. This compound features a complex structure containing a tetrazole ring and a benzyl ether moiety, which are critical for its pharmacological activity and metabolic stability.
The primary therapeutic application of Candesartan cilexetil lies in the management of hypertension and heart failure. As a prodrug, it exhibits low oral bioavailability in its original form; however, upon administration, it undergoes rapid hydrolysis in the gastrointestinal tract to release the active metabolite, candesartan. Once absorbed, candesartan selectively blocks the binding of angiotensin II to the AT1 receptors located on vascular smooth muscle cells and adrenal glands. This blockade inhibits vasoconstriction and aldosterone secretion, effectively lowering blood pressure and reducing cardiac workload without affecting bradykinin metabolism, thereby minimizing side effects like cough commonly associated with ACE inhibitors.
In the context of Good Manufacturing Practice (GMP), high-purity Candesartan cilexetil is essential for ensuring patient safety and treatment efficacy. Manufacturers adhering to GMP standards utilize Drug Master Files (DMF) to provide regulatory agencies with detailed data regarding synthesis, purity, stability, and quality control protocols. The "99% up" specification indicates that the product meets rigorous purity thresholds, typically exceeding 99%, which is crucial for tablet formulation and consistent dosing. This high-grade material is indispensable for generic drug manufacturers producing antihypertensive therapies worldwide. Furthermore, its inclusion in DMFs streamlines the regulatory approval process for new drug applications, facilitating faster market entry. The substance is stored under controlled conditions to prevent degradation, maintaining its integrity until final formulation. Overall, Candesartan cilexetil represents a cornerstone in cardiovascular pharmacotherapy, balancing high efficacy with a favorable safety profile for millions of patients suffering from chronic blood pressure disorders.
(All Rights Reserved)